Related Experiment Videos
Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy
1Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan. chiaki@med.yokohama-cu.ac.jp
Abstract:
The pathogenetic mechanism of neuroleptic malignant syndrome (NMS), a potentially lethal adverse effect of antipsychotics, is not well understood. In addition to acquired risk factors, clinical observations suggest a number of genetic factors predisposing patients to NMS. Recent findings in pharmacogenetics indicate that the genetic polymorphisms for drug-metabolizing enzymes, drug transporters, and possibly drug-targeting molecules, are associated with the interindividual differences in drug responses concerning both efficacy and adverse reactions. Genetic association studies have sought to identify polymorphisms influencing susceptibility to NMS, especially with respect to the dopamine D(2) receptor, serotonin receptor, and cytochrome p450 2D6. While a few candidate polymorphisms were associated with NMS, a large controlled study is needed to attain statistical power. On the other hand, NMS might include heterogeneous conditions with common characteristic symptoms but different causative mechanisms. Further analysis of individuals with identified genetic mutations or polymorphisms should advance our understanding of mechanisms underlying NMS.
Insights
Genetic factors influence susceptibility to neuroleptic malignant syndrome (NMS), a serious antipsychotic side effect. Further research into genetic polymorphisms is crucial for understanding NMS mechanisms and improving patient safety.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Clinical Pharmacology
Background:
- Neuroleptic malignant syndrome (NMS) is a severe adverse drug reaction to antipsychotics with poorly understood pathogenesis.
- Genetic predisposition is suspected, alongside acquired risk factors, in NMS development.
- Pharmacogenetics highlights the role of genetic variations in drug metabolism, transport, and targets, influencing individual responses.
Purpose of the Study:
- To explore the role of genetic factors, specifically polymorphisms, in susceptibility to neuroleptic malignant syndrome (NMS).
- To identify specific genetic polymorphisms associated with NMS risk, focusing on dopamine D(2) and serotonin receptors, and cytochrome P450 2D6.
- To emphasize the need for larger, controlled studies to confirm associations and understand NMS heterogeneity.
Main Methods:
- Review of existing literature on pharmacogenetics and NMS.
- Analysis of genetic association studies investigating polymorphisms in drug-metabolizing enzymes, transporters, and target molecules.
- Focus on candidate polymorphisms related to dopamine D(2) receptors, serotonin receptors, and CYP2D6.
Main Results:
- Some candidate genetic polymorphisms have shown preliminary associations with NMS susceptibility.
- Interindividual differences in drug response, including adverse reactions like NMS, are linked to genetic variations.
- Current findings suggest a need for larger, statistically powered studies to validate these associations.
Conclusions:
- Genetic polymorphisms in drug-related genes are implicated in NMS risk.
- NMS may represent a heterogeneous group of conditions with diverse underlying mechanisms.
- Further investigation of genetic mutations and polymorphisms in NMS patients is essential for elucidating causative pathways.